# VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma

> **NCT04151615** · — · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 203 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04151615
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-15
- **Primary completion:** 2023-01-11
- **Final completion:** 2023-01-11
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04151615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04151615, "VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04151615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*